People: Pacira Biosciences Inc (PCRX.OQ)
24 May 2019
Dr. Gary W. Pace, Ph.D., is Director of the Company. Dr. Pace has served as a director since June 2008. He was director to QRxPharma Ltd. (ASX: QRX) from 2001 to 2014. Dr. Pace has been a director of ResMed (NYSE: RMD) since 1994 and Transition Therapeutics Inc. (CDNX: TTH) since 2002. He previously served as a member of the board of directors at Celsion Corporation (NASDAQ: CLSN) from 2002 to 2010 and Peplin Inc. (ASX: PLI) from 2004 to 2009. He has more than 40 years of experience in the development and commercialization of advanced technologies, spanning biotechnology, pharmaceuticals, medical devices, and food industries. Dr. Pace was awarded a Centenary Medal by the Australian Government in 2003 "for service to Australian society in research and development" and was recognized as the 2011 Director of the Year (corporate governance) by the Corporate Directors Forum. Dr. Pace holds a B.Sc. with honors from the University of New South Wales and a Ph.D. from Massachusetts Institute of Technology.
|Total Annual Compensation, USD||56,000|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||115,829|
|Fiscal Year Total, USD||171,829|